Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline and multifaceted neuropathology. Although fluid biomarkers cerebrospinal fluid (CSF) amyloid-β and tau and imaging biomarkers positron emission tomography (PET) have substantially advanced AD diagnostics, electroencephalography (EEG) remains a comparatively underutilized tool despite its unique potential. EEG biomarkers capture oscillatory abnormalities (oscillopathies), providing a dynamic wi